BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ranbaxy Laboratories's Joint Venture In Japan Launches Generic Clarithromycin & Terbinafine Tablets


7/17/2006 12:54:07 PM

PRINCETON, N.J., July 17 /PRNewswire/ -- Ranbaxy Laboratories Limited (RLL) today announced that Nihon Pharmaceutical Industry Ltd. (NPI), a Joint Venture between RLL and Nippon Chemiphar Limited (NC) in Japan, has successfully launched Clarithromycin 50mg, 200mg tablets (Innovator- Taisho/Dinabbot; Brand name Clarith/Klaricid) and Terbinafine 125mg tablets (Innovator - Novartis; Brand name Lamisil).

Clarithromycin is an antibiotic and Terbinafine, an antifungal with a market size of around US$400 Million and US$300 Million respectively, in Japan, for the above dosage forms. The products will be sold in Japan under the Ranbaxy/Nihon Pharmaceutical Industry Limited label and will be marketed and actively promoted to doctors in hospitals as well as in clinics jointly by the field forces of NC and NPI.

Commenting on the launch, Mr. Malvinder Mohan Singh, CEO & Managing Director, RLL, said, "It is our earnest intention to leverage the advantage of an early entry in the progressive opening up of the generic pharma market of Japan. We intend to rapidly introduce an array of generic therapies from our global portfolio."

Mr. Atul Sobti, President, Asia, API Sales & Purchasing and Global Consumer Healthcare, RLL, said, "Following the successful launch of Vogseal for Diabetes, we have now introduced Clarithromycin and Terbinafine and expect an encouraging response. The Joint Venture, NPI, reflects our strong relationship as well as strategic techno commercial partnership between Ranbaxy and Nippon Chemiphar. Together we will continue to increase the momentum on the product filings in the coming years and bring in more products to the growing Japanese pharmaceutical market."

Ranbaxy entered the Japanese market in the year 2002 through a strategic alliance with a mid sized research pharmaceutical company, Nippon Chemiphar Limited (NC) of Japan. In July 2005, the JV introduced its first co-developed product Vogseal 0.2mg and 0.3mg tablets (Generic-Voglibose) for the treatment of diabetes and presently commands a leadership position in Japan. In November 2005 the Company increased its equity stake in its generic subsidiary Nihon Pharmaceutical Industry Limited (NPI) to become a 50:50 joint venture between Ranbaxy and Nippon Chemiphar.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 8 countries.

For further information please contact: Ramesh L. Adige Whole-time Director- Corporate Affairs and Global Corporate Communications Ranbaxy Laboratories Ltd. Plot 90, Sector 32, Gurgaon Haryana122001, India Tel: +91-124-4135000 e-mail: ramesh.adige@ranbaxy.com or Raghu Kochar Director-Corporate Communications Ranbaxy Laboratories Ltd. Plot 90, Sector 32, Gurgaon Haryana122001, India Tel: +91-124-4135141 Mobile: 9811617256 e-mail: raghu.kochar@ranbaxy.com or Krishnan Ramalingam Sr. Manager- Corporate Communications Ranbaxy Laboratories Ltd. Plot 90, Sector 32, Gurgaon Haryana122001, India Tel: +91-124-4135143 Mobile: 9810042540 e-mail: krishnan.ramalingam@ranbaxy.com

Ranbaxy Laboratories Limited

CONTACT: Ramesh L. Adige, Whole-time Director- Corporate Affairs andGlobal Corporate Communications, +91-124-4135000, ramesh.adige@ranbaxy.com;or Raghu Kochar, Director-Corporate Communications, +91-124-4135141,Mobile: +9811617256, raghu.kochar@ranbaxy.com; or Krishnan Ramalingam, Sr.Manager- Corporate Communications, +91-124-4135143, Mobile: +9810042540,krishnan.ramalingam@ranbaxy.com, all of Ranbaxy Laboratories Ltd.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES